Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management
Drugs · 2024-10 · 84 (10) · 1179-1197
DOI: 10.1007/s40265-024-02094-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 26.09.2024. Verfasst von Konstantina Kitsou und 3 weiteren Autor:innen. Beteiligte Einrichtung: National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Lysophospholipids, Sphingosine, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIDDK NIH HHS.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) are chronic immune-mediated diseases which primarily target the intestines. In recent years, the development and regulatory approval of various immunotherapies, both biological agents and small molecules, that target specific pathways of the IBD-associated inflammatory cascade have revolutionized the treatment of IBD. Small molecules offer the advantages of oral administration and short wash-out times. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of ceramide, which exerts its functions after binding to five G-protein-coupled receptors (S1PR1-S1PR5). Concerning IBD, S1P participates in the egress of lymphocytes from the secondary lymphoid tissue and their re-circulation to sites of inflammation, mainly through S1PR1 binding. In addition, this system facilitates the differentiation of T-helper cells towards proinflammatory immunophenotypes. Recently, S1P modulators have offered a valuable addition to the IBD treatment armamentarium. They exert their anti-inflammatory function via sequestration of T cell subsets in the lymphoid tissues and prevention of gut homing. In this review, we revisit the role of the S1P/S1PR axis in the pathogenesis of IBD and discuss efficacy and safety data from clinical trials and real-world reports on the two S1PR modulators, ozanimod and etrasimod, that are currently approved for IBD treatment, and comment on their potential positioning in the IBD day-to-day management. We also present recent data on emerging S1P modulators. Finally, based on the successes and failures of S1PR modulators in IBD, we discuss future avenues of IBD treatments targeting the S1P/S1PR axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National and Kapodistrian University of Athens, Athens, Greece.
- GI-Unit, 3rd Department of Internal Medicine, Sotiria Hospital, 152 Mesogeion Av., 11528, Athens, Greece.
- San Diego VA Medical Center (SDVAMC), San Diego, CA, USA.
- Division of Gastroenterology, Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
- GI-Unit, 3rd Department of Internal Medicine, Sotiria Hospital, 152 Mesogeion Av., 11528, Athens, Greece. gbamias@gmail.com.
Förderung
- BLRD VA
- NIDDK NIH HHS
Zitieren
APA
Kitsou, K., Kokkotis, G., Rivera-Nieves, J., & Bamias, G. (2024). Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management. Drugs, 84(10), 1179-1197. https://doi.org/10.1007/s40265-024-02094-5
Vancouver
Kitsou K, Kokkotis G, Rivera-Nieves J, Bamias G. Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management. Drugs. 2024;84(10):1179-1197. doi:10.1007/s40265-024-02094-5
BibTeX
@article{Kitsou2024,
author = {Kitsou, Konstantina and Kokkotis, Georgios and Rivera-Nieves, Jesús and Bamias, Giorgos},
title = {Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management},
journal = {Drugs},
year = {2024},
volume = {84},
number = {10},
pages = {1179--1197},
doi = {10.1007/s40265-024-02094-5}
}
EUVIMED